RecruitingPhase 2NCT06668792
An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma
Studying Plasma cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biocad
- Intervention
- BCD-248(drug)
- Enrollment
- 100 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (20)
- SBHI of the Kaliningrad region "Central City Clinical Hospital", Kaliningrad, Russia
- SAHI "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigala", Kazan', Russia
- FSBI of science "Kirov research Institute of Hematology and blood transfusion of the Federal medical and biological Agency", Kirov, Russia
- Regional Government-Owned Publicly Funded Healthcare Institution "Regional Clinical Hospital", Krasnoyarsk, Russia
- Branch of the limited liability company "Hadassah Medical LTD", Moscow, Russia
- City Clinical Hospital №52 of the Department of Health of the City of Moscow, Moscow, Russia
- FSBI "National Medical Research Center of Oncology named after N. N. Blokhin" of the Ministry of Health of the Russian Federation, Moscow, Russia
- JSC "Medsi Group of Companies", Moscow, Russia
- SBI of health care of the city of Moscow city clinical hospital named after S. P. Botkin of the Department of health of the City of Moscow, Moscow, Russia
- State budgetary healthcare Institution of the Moscow Region "Moscow Regional Research Clinical Institute named after M. F. Vladimirsky", Moscow, Russia
- Federal State Budgetary Institution "National Medical Research Center for Radiology" of the Ministry of Health of the Russian Federation, Obninsk, Russia
- SBHI of the Republic of Karelia "Republican Hospital named after V.A. Baranov", Petrozavodsk, Russia
- FSBI "Almazov National Medical Research Centre" of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia
- FSBEI of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation, Samara, Russia
- FSBEI HE "Saratov State Medical University named after V.I. Razumovsky" of the Ministry of Health of Russia, Saratov, Russia
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06668792 on ClinicalTrials.govOther trials for Plasma cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07446777FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor DiseaseUniversity of Miami
- RECRUITINGPHASE1NCT07333261Study of BMS-986453 in Newly Diagnosed Multiple MyelomaSusan Bal
- RECRUITINGPHASE3NCT07258511A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaJanssen Research & Development, LLC
- RECRUITINGPHASE1NCT07093554Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple MyelomaMedical College of Wisconsin
- RECRUITINGPHASE2NCT06920251Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab TherapySeoul National University Hospital
- RECRUITINGPHASE2NCT06822972HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMMDuke University
- RECRUITINGNANCT07045727Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple MyelomaMayo Clinic
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT07210047Study of HuL001 in Relapsed/Refractory Multiple Myeloma PatientsHuniLife Biotechnology, Inc.